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Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Doug Klein RN, BSN
Otterbein University, Westerville, Ohio
Introduction

Stevens-Johnson Syndrome (SJS) and
Toxic Epidermal Necrolysis (TEN) are rare,
cutaneous, severe, drug-induced
hypersensitivity reactions marked by
widespread inflammation of the
epidermis, ending in necrosis and the
eventual sloughing of tissue. First
described in 1922 by pediatricians Albert
Stevens and Frank Johnson, both diseases
are believed to be as a result of the same
disease process. They are the most serious
of all drug-related hypersensitivity
reactions which result in hospitalization
(Ferrandiz-Perez & Garcia-Patos, 2013).
As a critical care nurse caring for a
variety of trauma patients, it is crucial that
staff is aware of potentially serious
medication reactions. Some of the most
serious of these start out with vague
symptoms and may appear benign.
However, some are very serious and
potentially fatal.

Pathophysiology-Overview
SJS/TEN disease has long been presumed to appear as a result
of an immune-mediated response to certain drug metabolites,
although the exact mechanism of action has been poorly
understood. Evidence has established a genetic predisposition for
illness to various Asian populations, leading to FDA
recommendations for pre-therapy genetic testing. Additional
research has focused on the effects Vitamin A derivatives have on
the disease process.

Pathophysiology

Retinoid and Granulysin-mediated hypothesis
Of Stevens-Johnsons Syndrome/Toxic
Epidermal Necrolysis (SJS/TEN)
(Mawson, et al, 2015)

Signs and Symptoms
Early signs/symptoms:
• Fever, malaise, fatigue and mucosal
lesions, headache, bleeding
Later signs/symptoms:
• Marked erythema of skin leading to
papules, vesicles and necrosis. These
start on the face neck and anterior
trunk and may extend over the entire
surface of the skin.
• Mucosal involvement, including ocular,
GI, GU, genital and upper and the
epithelial cells of the lower respiratory
tree. These areas are associated with
heavy bleeding , scarring and long-term
complications.

Progression of SJS/TEN

Statistics

Disease

TBSA %

Mortality

Incidence/million

SJS

<10%

5%

2-6

TEN

>30%

30%

0.2-1.2

(Mawson et al., 2015) (>10%, <30% is considered to be mixed SJS/TEN disease) (TBSA-total body surface area)

SJS/TEN is marked by the widespread eruption of macules and
papules which eventually lead to skin necrosis and sloughing.
Until recently, SJS/TEN has been thought to be an idiopathic
illness. Research seeking to clarify the genesis of the illness has
found that morbidity can be a result of a genetic predisposition to
a drug hypersensitivity reaction. Genetic research has identified
several combinations of Alleles and medications which when
combined, increase the risk of illness. Further research has sought
understanding into the disease pathophysiology. In a paper
published by Mawson, Eriator and Karre (2015), the authors
theorize that disease occurs when a drug metabolite damages the
liver, the organ responsible for storage of Vitamin A, causing freeretinoid molecules to spill into the circulation creating an acute,
systemic Vitamin A toxicity. Granulysin, a cytotoxic protein
produced in massive quantities by both CD8+ T-Lymphocytes and
natural killer cells is the most prevalent molecule found in SJS/TEN
blisters. Granulysin is believed to act as a cytokine for destructive
retinoid molecules (such as retinoic acid), combined together are
believed to be responsible for keratinocyte apoptosis seen in
SJS/TEN. As keratinocytes die off, the epidermis becomes
detached from the dermis ending in tissue necrosis and sloughing
(Teo & Walsh, 2016). Although not fully understood, the authors
theorize that CD8+ T-cells become hyperactive when exposed to
extreme levels of retinol and overproduce Granulysin. Granulysin
then attracts retinoic acid which are both cytotoxic and together
cause keratinocytes to die off. Keratinocytes make up 90% of the
cells in the epidermis.
Many classes of medications have been linked to SJS/TEN,
including anticonvulsants, antibiotics, NSAIDS, corticosteroids and
allopurinol. These medications increase circulating retinoid levels,
either through hepatic release as a result of liver injury, or through
the inhibition of metabolism which leads to higher circulating
retinol derivatives, such as retinoic acid, a powerful cell-lysing
agent (Mawson, Eriator, & Karre, 2015). Hepatic injury could
explain the extended prodromal illness seen in this disease as
patients often present with vague illness which typically lasts for
over a week prior to the onset of the more identifiable rash.

Implications: Pathophysiology
Understanding pathophysiology is key for treating and limiting
the destructive mechanism for disease. Provided that retinol
toxicity is involved with SJS/TEN, plasmapheresis could be used to
reduce circulating levels and mitigate the destructive effects
which retinol contributes in this disease. Plasmapheresis has
been shown in small samples to reduce mortality versus typical
treatment for patients with SJS/TEN (Mawson, 2015).
Genetic predispositions have been positively established for
people of Asian descent who carry the HLA-B1502 Allele when
exposed to Carbamazepine. The FDA recommends genetic
testing prior to starting Asian patients on Carbamazepine therapy
(Tangamornsukan, Chalyakunapruk, Somkrua, Lohitnavy, &
Tassaneeyakui, 2013). Studies have also linked a higher than
normal incidence of SJS/TEN within the Indian population,
particularly is they are HIV-positive (Patel, Barvaliya, Sharma &
Tripathi, 2013). HLA-A3101 has recently been identified as a
phenytoin-associated risk among Japanese and Europeans
(Pirmohamed et al., 2011). Understanding genetic associations
can help healthcare providers the mitigate risk through pretherapy testing.

Nursing: Implications:
Rapid identification of disease is crucial for patients
suffering from SJS/TEN as removal of the offending medication
is critical for mitigating the effects of the illness. Nursing
should familiarize themselves with the symptoms and signs of
progression as illness may advance quickly from SJS to TEN in
as few as twelve hours (Poulson, Nielsen, & Poulsen, 2013).
• Nursing should be watchful for signs or symptoms of
decompensation due to respiratory failure or sepsis.
• Pain management and the use of conscious sedation,
especially during debridement and dressing changes will
improve healing and health outcomes.
• Treatment is best done in a specialized burn center.
• The nurse should seek to coordinate a multi-disciplinary
team approach(Cooper, 2012).
• Long-term restrictive pulmonary disease is frequently seen
with SJS/TEN and patients will often require long-term use
of bronchodilators (British Journal of Medicine, 2015).

Conclusions:
Although SJS/TEN has been recognized illness for decades,
recent advancements in genetics have identified strong
predispositions to certain drug reactions, helping guide
prescribers prior toward safe and effective treatment. Patients
at risk should be tested for susceptibility before starting
therapy. The use of plasmapheresis should be studied further
to determine whether limiting free-retinoid compounds could
mitigate the damage caused by disease.
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